Base de dados : MEDLINE
Pesquisa : D02.886.030.786 [Categoria DeCS]
Referências encontradas : 6977 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 698 ir para página                         

  1 / 6977 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28579033
[Au] Autor:Zhang J; Yan H; Lou MF
[Ad] Endereço:Department of Ophthalmology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; School of Veterinary Medicine and Biomedical Sciences, Lincoln, NE, USA.
[Ti] Título:Does oxidative stress play any role in diabetic cataract formation? ----Re-evaluation using a thioltransferase gene knockout mouse model.
[So] Source:Exp Eye Res;161:36-42, 2017 Aug.
[Is] ISSN:1096-0007
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Oxidative stress is a known risk factor in senile cataract formation. In recent years, it has been suggested that oxidation may also be associated with cataract induced by hyperglycemia, but this concept has not been well examined or validated. Since thioltransferase (TTase) is one of the key enzymes that regulates redox homeostasis and protects against oxidative stress in the lens, we have used TTase gene knockout (KO) mice as a model to examine this new concept. Lenses from 4 months old TTase KO and wild-type (WT) mice were incubated in TC199 culture medium containing 30 mM glucose for 48 h. Each lens was assessed for opacity, graded by LOCSII system, and the wet weight was recorded after which it was homogenized in lysis buffer and analyzed for water-soluble protein and free glutathione (GSH). In vivo studies were carried out using 4 months old TTase KO and WT mouse groups. Each mouse received two consecutive days of intraperitoneal streptozotozin (STZ) injections to induce diabetes. The lenses were examined weekly for 4 weeks using a slit-lamp biomicroscope, and then extracted and analyzed for levels of GSH, water-soluble protein, ATP and protein-GSH mixed disulfide (PSSG). TTase KO lenses cultured in high glucose developed a mild cortical opacity but slightly more than that of the WT lenses. Both groups had similar contents of soluble proteins and GSH. Exposure to high glucose did not change the soluble protein level but did suppress GSH by 20% in lenses with or without TTase. STZ-induced diabetic KO mice also developed a higher degree of mild cortical lens opacity compared to that of the diabetic WT controls. Similar 15-20% losses in lens GSH and ATP were found after one-month induced diabetes in WT and KO mice. There was a 20% greater amount of PSSG in the lenses of TTase KO than the WT control. Under diabetic condition, both groups displayed more glutathionylated proteins in the beta-actin (42 kDa) and lens crystallin proteins (18-22 kDa) regions, and some additional modified proteins at 15-17 kDa and 60-70 kDa, with a total 20-30% PSSG increment in both groups. In conclusion, we have found that hyperglycemia induced some oxidative stress-associated biochemical changes with mild lens opacity in both WT and KO mice. However, these changes were only marginally higher in the TTase KO mouse than that of the WT control, suggesting that TTase deletion may only play a minor role in the early stage of hyperglycemia-induced cataract formation in the mice.
[Mh] Termos MeSH primário: Catarata/metabolismo
Diabetes Mellitus Experimental/metabolismo
Modelos Animais de Doenças
Glutarredoxinas/genética
Estresse Oxidativo/fisiologia
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/metabolismo
Animais
Glicemia/metabolismo
Western Blotting
Catarata/etiologia
Catarata/patologia
Diabetes Mellitus Experimental/etiologia
Diabetes Mellitus Experimental/patologia
Dissulfetos/metabolismo
Eletroforese em Gel de Poliacrilamida
Técnicas de Inativação de Genes
Glutationa/análogos & derivados
Glutationa/metabolismo
Dissulfeto de Glutationa/metabolismo
Peróxido de Hidrogênio/farmacologia
Hiperglicemia/complicações
Cristalino/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Penicilamina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Disulfides); 0 (Glutaredoxins); 8L70Q75FXE (Adenosine Triphosphate); 92000-26-5 (penicillamine-glutathione mixed disulfide); BBX060AN9V (Hydrogen Peroxide); GAN16C9B8O (Glutathione); GNN1DV99GX (Penicillamine); ULW86O013H (Glutathione Disulfide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE


  2 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28350426
[Au] Autor:Saffioti F; Gurusamy KS; Eusebi LH; Tsochatzis E; Davidson BR; Thorburn D
[Ad] Endereço:Sheila Sherlock Liver Centre, Royal Free Hospital and the UCL Institute of Liver and Digestive Health, Pond Street, Hampstead, London, UK, NW3 2QG.
[Ti] Título:Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
[So] Source:Cochrane Database Syst Rev;3:CD011648, 2017 03 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Primary biliary cholangitis (previously primary biliary cirrhosis) is a chronic liver disease caused by the destruction of small intra-hepatic bile ducts resulting in stasis of bile (cholestasis), liver fibrosis, and liver cirrhosis. The optimal pharmacological treatment of primary biliary cholangitis remains uncertain. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions in the treatment of primary biliary cholangitis through a network meta-analysis and to generate rankings of the available pharmacological interventions according to their safety and efficacy. However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not perform the network meta-analysis, and instead, assessed the comparative benefits and harms of different interventions using standard Cochrane methodology. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised controlled trials registers to February 2017 to identify randomised clinical trials on pharmacological interventions for primary biliary cholangitis. SELECTION CRITERIA: We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with primary biliary cholangitis. We excluded trials which included participants who had previously undergone liver transplantation. We considered any of the various pharmacological interventions compared with each other or with placebo or no intervention. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. We calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CI) using both fixed-effect and random-effects models based on available-participant analysis with Review Manager 5. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE. MAIN RESULTS: We identified 74 trials including 5902 participants that met the inclusion criteria of this review. A total of 46 trials (4274 participants) provided information for one or more outcomes. All the trials were at high risk of bias in one or more domains. Overall, all the evidence was low or very low quality. The proportion of participants with symptoms varied from 19.9% to 100% in the trials that reported this information. The proportion of participants who were antimitochondrial antibody (AMA) positive ranged from 80.8% to 100% in the trials that reported this information. It appeared that most trials included participants who had not received previous treatments or included participants regardless of the previous treatments received. The follow-up in the trials ranged from 1 to 96 months.The proportion of people with mortality (maximal follow-up) was higher in the methotrexate group versus the no intervention group (OR 8.83, 95% CI 1.01 to 76.96; 60 participants; 1 trial; low quality evidence). The proportion of people with mortality (maximal follow-up) was lower in the azathioprine group versus the no intervention group (OR 0.56, 95% CI 0.32 to 0.98; 224 participants; 2 trials; I = 0%; low quality evidence). However, it has to be noted that a large proportion of participants (25%) was excluded from the trial that contributed most participants to this analysis and the results were not reliable. There was no evidence of a difference in any of the remaining comparisons. The proportion of people with serious adverse events was higher in the D-penicillamine versus no intervention group (OR 28.77, 95% CI 1.57 to 526.67; 52 participants; 1 trial; low quality evidence). The proportion of people with serious adverse events was higher in the obeticholic acid plus ursodeoxycholic acid (UDCA) group versus the UDCA group (OR 3.58, 95% CI 1.02 to 12.51; 216 participants; 1 trial; low quality evidence). There was no evidence of a difference in any of the remaining comparisons for serious adverse events (proportion) or serious adverse events (number of events). None of the trials reported health-related quality of life at any time point. FUNDING: nine trials had no special funding or were funded by hospital or charities; 31 trials were funded by pharmaceutical companies; and 34 trials provided no information on source of funding. AUTHORS' CONCLUSIONS: Based on very low quality evidence, there is currently no evidence that any intervention is beneficial for primary biliary cholangitis. However, the follow-up periods in the trials were short and there is significant uncertainty in this issue. Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid post-randomisation dropouts or planned cross-overs; should have sufficient follow-up period (e.g. five or 10 years or more); and use clinically important outcomes such as mortality, health-related quality of life, cirrhosis, decompensated cirrhosis, and liver transplantation. Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.
[Mh] Termos MeSH primário: Colangite/tratamento farmacológico
[Mh] Termos MeSH secundário: Azatioprina/efeitos adversos
Azatioprina/uso terapêutico
Ácido Quenodesoxicólico/efeitos adversos
Ácido Quenodesoxicólico/análogos & derivados
Ácido Quenodesoxicólico/uso terapêutico
Colagogos e Coleréticos/efeitos adversos
Colagogos e Coleréticos/uso terapêutico
Colangite/imunologia
Colangite/mortalidade
Doença Crônica
Colchicina/efeitos adversos
Colchicina/uso terapêutico
Ciclosporina/efeitos adversos
Ciclosporina/uso terapêutico
Seres Humanos
Imunossupressores/efeitos adversos
Imunossupressores/uso terapêutico
Metotrexato/efeitos adversos
Metotrexato/uso terapêutico
Mitocôndrias/imunologia
Metanálise em Rede
Penicilamina/efeitos adversos
Penicilamina/uso terapêutico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Ácido Ursodesoxicólico/efeitos adversos
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Immunosuppressive Agents); 0462Z4S4OZ (obeticholic acid); 0GEI24LG0J (Chenodeoxycholic Acid); 724L30Y2QR (Ursodeoxycholic Acid); 83HN0GTJ6D (Cyclosporine); GNN1DV99GX (Penicillamine); MRK240IY2L (Azathioprine); SML2Y3J35T (Colchicine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011648.pub2


  3 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28301671
[Au] Autor:Zhang D
[Ad] Endereço:Henan Provincial People's Hospital, Zhengzhou, Henan Province, China tengjunfang@tom.com.
[Ti] Título:A clinical study of bone mesenchymal stem cells for the treatment of hepatic fibrosis induced by hepatolenticular degeneration.
[So] Source:Genet Mol Res;16(1), 2017 Mar 15.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The efficacy of bone marrow mesenchymal stem cell (BMSC) on liver fibrosis in animal has been proven, but a few studies have been made in human body and few such researches in China. This study was designed to investigate the effect of BMSC treatment on hepatic fibrosis induced by hepatolenticular degeneration and the influence on serological indicators. Sixty patients with liver fibrosis induced by hepatolenticular degeneration were randomly divided into two groups, a penicillamine group and a BMSCs plus penicillamine group, with 30 patients in each. The therapeutic effects on hepatic fibrosis, liver function, and serological indicators were recorded before and after the treatment, and the data were compared. After treatment, serum levels of HA, PCIII, LN, CIV, TIMP-1, and MMP-1 were reduced in both groups (P < 0.05). However, cytokine levels in the BMSCs plus penicillamine group were significantly lower than those in the penicillamine group (P < 0.05). Combination therapy with BMSCs and penicillamine had a significant positive effect on liver fibrosis induced by hepatolenticular degeneration.
[Mh] Termos MeSH primário: Degeneração Hepatolenticular/terapia
Cirrose Hepática/terapia
Transplante de Células-Tronco Mesenquimais
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Estudos de Casos e Controles
Células Cultivadas
Quelantes/administração & dosagem
Terapia Combinada
Feminino
Degeneração Hepatolenticular/sangue
Degeneração Hepatolenticular/complicações
Seres Humanos
Fígado/metabolismo
Fígado/patologia
Cirrose Hepática/sangue
Cirrose Hepática/etiologia
Masculino
Células Mesenquimais Estromais/fisiologia
Penicilamina/administração & dosagem
Fator de Crescimento Transformador beta1/sangue
Resultado do Tratamento
Fator de Necrose Tumoral alfa/sangue
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chelating Agents); 0 (TGFB1 protein, human); 0 (TNF protein, human); 0 (Transforming Growth Factor beta1); 0 (Tumor Necrosis Factor-alpha); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.4238/gmr16019352


  4 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28274189
[Au] Autor:Malfatti CR; Dos Santos FS; Wouk J; da Silva LA; Michel RG; Snak AL; Czervinski T; da Cunha MA; Barbosa AM; Dekker RF
[Ad] Endereço:a Pharmaceutical Science Postgraduate Program , Midwest State University, Campus CEDETEG , Guarapuava , Brazil.
[Ti] Título:Intracerebroventricular administration of the (1→6)-ß-d-glucan (lasiodiplodan) in male rats prevents d-penicillamine-induced behavioral alterations and lipoperoxidation in the cortex.
[So] Source:Pharm Biol;55(1):1289-1294, 2017 Dec.
[Is] ISSN:1744-5116
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Lasiodiplodan, an exocellular (1→6)-ß-d-glucan of molecular weight >1.4 × 10 Da produced by MMPI strain of Lasiodiplodia theobromae (Pat.) Griffon & Maubl. (Brotyosphaeriaceae) is known to exhibit anti-proliferative activity on breast cancer cells (MCF-7), anticoagulant activity when sulfonylated, and reduction in transaminase activity when administered in rats. OBJECTIVE: The effect of intracerebroventricular (I.C.V) injection of lasiodiplodan on neurotoxicity and behavioural changes induced by d-penicillamine was investigated. MATERIALS AND METHODS: Twenty-four male Wistar rats were initially separated in groups of six and treated with 0.15 µmol/µL of NaCl (Groups Ct and d-Pen) and 0.01 µg/µL of lasiodiplodan (Groups Las and Las + d-Pen). After 15 min, they received 6 µmol/µL of NaCl (Groups Ct and Las) and 2 µmol/µL of d-penicillamine (Groups d-Pen and Las + d-Pen). The animal behavior was observed in an open-field test for 60 min. Twenty-four h later, the animals were sacrificed and histopathological analysis and Thiobarbituric acid reactive substances (TBARS) production measurements were performed. RESULTS: Lasiodiplodan prevented neurotoxicity induced by d-penicillamine significantly reducing the production of TBARS (308%; p < 0.05), and behavioural signs; convulsive and pre-convulsive. No histopathological alterations in the cerebral cortex were observed. DISCUSSION AND CONCLUSION: The reduction of TBARS production and convulsive episodes suggests that the protector effect provided by lasiodiplodan passes thought an antioxidant path, possibly interfering in a cascade of neurochemical events, triggering cell death and convulsive episodes. These results demonstrated that lasiodiplodan can be effective in treating neurotoxicity, and reducing damage triggered by convulsions in neuropathies related to GABAergic system.
[Mh] Termos MeSH primário: Comportamento Animal/efeitos dos fármacos
Córtex Cerebral/efeitos dos fármacos
Peroxidação de Lipídeos/efeitos dos fármacos
Fármacos Neuroprotetores/administração & dosagem
Penicilamina/toxicidade
Zearalenona/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Comportamento Animal/fisiologia
Córtex Cerebral/metabolismo
Injeções Intraventriculares
Peroxidação de Lipídeos/fisiologia
Masculino
Distribuição Aleatória
Ratos
Ratos Wistar
Zearalenona/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuroprotective Agents); 0 (lasiodiplodin); 5W827M159J (Zearalenone); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170316
[Lr] Data última revisão:
170316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/13880209.2017.1299767


  5 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28220734
[Au] Autor:Yudelowitz G
[Ad] Endereço:Tambo Memorial Hospital, Boksburg, South Africa. gregyudels@gmail.com.
[Ti] Título:Intentional intravenous mercury injection.
[So] Source:S Afr Med J;107(2):112-114, 2017 Jan 30.
[Is] ISSN:0256-9574
[Cp] País de publicação:South Africa
[La] Idioma:eng
[Ab] Resumo:Mercury toxicity is commonly associated with vapour inhalation or oral ingestion, for which there exist definite treatment options.Intravenous mercury injection is rarely seen, with few documented cases. Treatment strategies are not clearly defined for such cases,although a few options do show benefit. This case report describes a 29-year-old man suffering from bipolar disorder, who presentedfollowing self-inflicted intravenous injection of mercury. Clinical and radiographic features, possible adverse clinical sequelae in preexistingmental illness and further complications are discussed, as well as possible treatment strategies in light of relevant literature.
[Mh] Termos MeSH primário: Lesão Renal Aguda/induzido quimicamente
Vasos Sanguíneos/diagnóstico por imagem
Intoxicação por Mercúrio/diagnóstico por imagem
[Mh] Termos MeSH secundário: Abdome/diagnóstico por imagem
Adulto
Transtorno Bipolar/psicologia
Quelantes/uso terapêutico
Antebraço/diagnóstico por imagem
Seres Humanos
Injeções Intravenosas
Masculino
Intoxicação por Mercúrio/sangue
Intoxicação por Mercúrio/tratamento farmacológico
Penicilamina/uso terapêutico
Radiografia
Radiografia Torácica
Tentativa de Suicídio/psicologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chelating Agents); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.7196/SAMJ.2017.v107i2.12046


  6 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Barbosa, Egberto Reis
Texto completo SciELO Brasil
[PMID]:28099566
[Au] Autor:Teive HA; Barbosa ER; Lees AJ
[Ad] Endereço:Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Neurologia, Unidade de Distúrbios dos Movimentos, Curitiba PR, Brasil.
[Ti] Título:Wilson's disease: the 60th anniversary of Walshe's article on treatment with penicillamine.
[So] Source:Arq Neuropsiquiatr;75(1):69-71, 2017 Jan.
[Is] ISSN:1678-4227
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:This historical review describes Professor Walshe's seminal contribution to the treatment of Wilson's disease on the 60th anniversary of his pioneering article on penicillamine, the first effective treatment for the condition.
[Mh] Termos MeSH primário: Pesquisa Biomédica/história
Degeneração Hepatolenticular/tratamento farmacológico
Degeneração Hepatolenticular/história
Penicilamina/história
Publicações Periódicas como Assunto/história
[Mh] Termos MeSH secundário: Boston
História do Século XX
Reino Unido
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; PORTRAITS
[Ps] Nome de pessoa como assunto:Walshe JM
[Nm] Nome de substância:
GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE


  7 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28063745
[Au] Autor:Dirksen K; Fieten H
[Ad] Endereço:Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
[Ti] Título:Canine Copper-Associated Hepatitis.
[So] Source:Vet Clin North Am Small Anim Pract;47(3):631-644, 2017 May.
[Is] ISSN:1878-1306
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Copper-associated hepatitis is recognized with increasing frequency in dogs. The disease is characterized by centrolobular hepatic copper accumulation, leading to hepatitis and eventually cirrhosis. The only way to establish the diagnosis is by histologic assessment of copper distribution and copper quantification in a liver biopsy. Treatment with the copper chelator d-penicillamine is the most commonly used treatment. In addition, a low-copper/high-zinc diet can help prevent accumulation or reaccumulation of hepatic copper. Mutations in the copper metabolism genes COMMD1 or ATP7A and ATP7B have been associated with hepatic copper concentrations in Bedlington terriers and Labrador retrievers respectively. In the Labrador retriever, dietary copper intake contributes strongly to the disease phenotype.
[Mh] Termos MeSH primário: Doenças do Cão
Hepatite Animal
[Mh] Termos MeSH secundário: Animais
Biomarcadores/sangue
Biomarcadores/urina
Quelantes/uso terapêutico
Cobre/farmacologia
Doenças do Cão/diagnóstico
Doenças do Cão/genética
Doenças do Cão/fisiopatologia
Doenças do Cão/terapia
Cães
Hepatite Animal/diagnóstico
Hepatite Animal/genética
Hepatite Animal/fisiopatologia
Hepatite Animal/terapia
Seres Humanos
Penicilamina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chelating Agents); 789U1901C5 (Copper); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170109
[St] Status:MEDLINE


  8 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27957879
[Au] Autor:Mehta V; Midha V; Mahajan R; Narang V; Wander P; Sood R; Sood A
[Ad] Endereço:a Department of Gastroenterology , Dayanand Medical College , Ludhiana , India.
[Ti] Título:Lead intoxication due to ayurvedic medications as a cause of abdominal pain in adults.
[So] Source:Clin Toxicol (Phila);55(2):97-101, 2017 Feb.
[Is] ISSN:1556-9519
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Though a majority of cases of lead intoxication come from occupational exposures, traditional and folk remedies have also been reported to contain toxic amounts of lead. We present a large series of patients with lead poisoning due to intake of Ayurvedic medicines, all of whom presented with unexplained abdominal pain. METHODOLOGY: This was a retrospective, observational case series from a tertiary care center in India. The charts of patients who underwent blood lead level (BLL) testing as a part of workup for unexplained abdominal pain between 2005 and 2013 were reviewed. The patients with lead intoxication (BLLs >25 µg/dl) were identified and demographics, history, possible risk factors, clinical presentation and investigations were reviewed. Treatment details, duration, time to symptomatic recovery, laboratory follow-up and adverse events during therapy were recorded. RESULTS: BLLs were tested in 786 patients with unexplained abdominal pain and high levels were identified in 75 (9.5%) patients, of which a majority (73 patients, 9.3%) had history of Ayurvedic medication intake and only two had occupational exposure. Five randomly chosen Ayurvedic medications were analyzed and lead levels were impermissibly high (14-34,950 ppm) in all of them. Besides pain in abdomen, other presenting complaints were constipation, hypertension, neurological symptoms and acute kidney injury. Anemia and abnormal liver biochemical tests were observed in all the 73 patients. Discontinuing the Ayurvedic medicines and chelation with d-penicillamine led to improvement in symptoms and reduction in BLLs in all patients within 3-4 months. CONCLUSION: The patients presenting with severe recurrent abdominal pain, anemia and history of use of Ayurvedic medicines should be evaluated for lead toxicity. Early diagnosis in such cases can prevent unnecessary investigations and interventions, and permits early commencement of the treatment.
[Mh] Termos MeSH primário: Dor Abdominal/etiologia
Intoxicação por Chumbo/etiologia
Chumbo/sangue
Medicina Ayurvédica
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anemia/epidemiologia
Anemia/etiologia
Quelantes/uso terapêutico
Feminino
Seguimentos
Seres Humanos
Índia
Intoxicação por Chumbo/tratamento farmacológico
Masculino
Penicilamina/uso terapêutico
Estudos Retrospectivos
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Chelating Agents); 2P299V784P (Lead); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161214
[St] Status:MEDLINE
[do] DOI:10.1080/15563650.2016.1259474


  9 / 6977 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27632698
[Au] Autor:Lin X; Zhu S; Wang Q; Xia Q; Ran P; Fu Y
[Ad] Endereço:Key Laboratory on Luminescence and Real-Time Analysis, Ministry of Education, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China.
[Ti] Título:Chiral recognition of penicillamine enantiomers using hemoglobin and gold nanoparticles functionalized graphite-like carbon nitride nanosheets via electrochemiluminescence.
[So] Source:Colloids Surf B Biointerfaces;148:371-376, 2016 Dec 01.
[Is] ISSN:1873-4367
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A new stable and stereo-selective electrochemiluminescence (ECL) interface has been designed for specific recognition of penicillamine (Pen) enantiomers by using hemoglobin (Hb) and gold nanoparticles functionalized graphite-like carbon nitride nanosheets composite (Au-g-C N NHs) modified glassy carbon electrodes (Hb/Au-g-C N /GCE). The advantages of Hb as chiral selector and Au-g-C N NHs as luminophore were perfectly displayed in this novel interface. The obviously different ECL intensity was exhibited after l-Pen and d-Pen adsorbed on Hb/Au-g-C N /GCE, and a larger response was observed on d-Pen/Hb/Au-g-C N /GCE. Under the optimum conditions, the developed ECL chiral sensor showed excellent analytical property for detection of Pen enantiomers in a linear range of 1.0×10 M to 5.0×10 M, and the detection limits of l-Pen and d-Pen were 3.1×10 M and 3.3×10 M (S/N=3) respectively. This work with high selectivity, stability and reproducibility may open a new door based on ECL to discriminate Pen enantiomers.
[Mh] Termos MeSH primário: Ouro/química
Hemoglobinas/química
Nanopartículas Metálicas/química
Nanoestruturas/química
Nitrilos/química
Penicilamina/análise
[Mh] Termos MeSH secundário: Adsorção
Técnicas Biossensoriais/métodos
Técnicas Eletroquímicas/métodos
Grafite/química
Concentração de Íons de Hidrogênio
Medições Luminescentes/métodos
Nanopartículas Metálicas/ultraestrutura
Microscopia de Força Atômica
Nanoestruturas/ultraestrutura
Penicilamina/química
Reprodutibilidade dos Testes
Espectrofotometria
Estereoisomerismo
Propriedades de Superfície
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hemoglobins); 0 (Nitriles); 534Q0F66RK (cyanogen); 7440-57-5 (Gold); 7782-42-5 (Graphite); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170910
[Lr] Data última revisão:
170910
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160916
[St] Status:MEDLINE


  10 / 6977 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27617526
[Au] Autor:Vajdi T; Lee WW; Paravar T
[Ad] Endereço:University of California, San Diego School of Medicine.
[Ti] Título:Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine.
[So] Source:Dermatol Online J;22(5), 2016 May 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Penicillamine-induced skin changes are rare and include: hypersensitivity reactions, autoimmune reactions, and cutaneous elastoses. We report a case of a 73-year-old man with cystinuria taking penicillamine for over 50 years who presented with penicillamine-induced cutis laxa and milia en plaque. A brief review of penicillamine induced skin changes, specifically cutis laxa and milia en plaque, is presented.
[Mh] Termos MeSH primário: Quelantes/efeitos adversos
Cútis Laxa/induzido quimicamente
Cistinúria/tratamento farmacológico
Penicilamina/efeitos adversos
Doenças das Glândulas Sudoríparas/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chelating Agents); GNN1DV99GX (Penicillamine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160913
[St] Status:MEDLINE



página 1 de 698 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde